Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Drug Found to Limit Allergic Reaction to Peanuts

By HospiMedica staff writers
Posted on 27 Mar 2003
A study has shown that an experimental drug can help people with peanut allergies avoid life-threatening reactions. More...
The study was published in the March 14, 2003, issue of The New England Journal of Medicine and was also presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Denver (CO, USA).

Food allergy symptoms can range from nausea and itching to anaphylactic shock and death. Researchers found that an anti-IgE antibody raised the average level at which study participants began reacting to peanuts, from about half a peanut to almost nine peanuts. They estimate that most of the 50-100 US annual fatal reactions to peanuts occur after an allergic person accidentally eats the equivalent of just one or two peanuts. Existing medications, including epinephrine, are taken only after the peanuts have been eaten and are not always effective.

The IgE molecule binds to a group of cells called mast cells, which then trigger the allergic response. The experimental drug, TNX-901, is a genetically engineered antibody that binds to the IgE molecule and prevents it from triggering allergic response. Stopping the response before it begins is considered a major advance. In the study, nearly a quarter of the patients receiving the highest dose of the drug consumed the equivalent of about 24 peanuts with no reaction. While many of them still reacted to peanuts after the injections, they could eat more peanuts without a reaction and reacted less vigorously to the peanuts they did eat.

TNX-901 was developed by Tanox (Houton, TX, USA). The study was conducted by researchers from the National Jewish Medical and Research Center (Denver, CO, USA) and the Mount Sinai School of Medicine (New York, NY, USA).

"Anti-IgE therapy is not a cure for peanut allergy,” said Hugh Sampson, M.D., of Mount Sinai School of Medicine. "But because the amount patients could consume without serious reaction would be greatly increased, the fear of accidental ingestion that detracts from quality of life for many patients would be eliminated.”





Related Links:
Tanox
National Jewish Medical and Research Center
Mount Sinai School of Medicine

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
OR Table Accessory
Angular Accessory Rail
Isolation Stretcher
IS 736
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.